ITCI (intracellulartherapies.com) יחס שווי שוק לשווי בספרים

This chart of the price-to-book ratio for Intra-Cellular Therapies (ITCI) demonstrates a margin of safety in assets, where the 12.14 mark characterizes this parameter. Intra-Cellular Therapies (ITCI) is reducing its reliance on a single product by introducing Caplyta into depression therapy. Revenue growth is based on the expansion of insurance programs and new research. Demand for medications for bipolar disorder and schizophrenia makes the business a defensive asset and independent of economic conditions.

A fundamental business valuation requires distinguishing market noise from the actual value of assets. This multiple compares the issuer's market value to its book value, determining the extent of capital overvaluation or undervaluation. By analyzing the current P/B ratio of the company, an investor can identify the market premium for growth potential. For Intra-Cellular Therapies (ITCI), this metric reflects market expectations for the commercial scaling of the drug Caplyta. The expansion of therapeutic indications in psychiatry is being directly capitalized, widening the gap between book value and the exchange price.